Article
Clinical development of IDH1 inhibitors for cancer therapy.
Cancer treatment reviews - 1 Feb 2022
Zarei Mehrdad, Hue Jonathan J, Hajihassani Omid, Graor Hallie J, Katayama Erryk S, Loftus Alexander W, Bajor David, Rothermel Luke D, Vaziri-Gohar Ali, Winter Jordan M
Abstract excerpt
Isocitrate dehydrogenase 1 (IDH1) has been investigated as a promising therapeutic target in select cancers with a mutated version of the enzyme (mtIDH1). With only one phase III trial published to date and two indications approved for routine clinical use by the FDA, we reviewed the entire clinical trial portfolio to broadly understand mtIDH1 inhibitor activity in patients. We queried PubMed.gov and...
Topics
Join the communities discussing this publication.